Haematologica, Vol 92, Issue 8, 1151-1152 doi:10.3324/haematol.11235
Copyright © 2007 by Ferrata Storti Foundation
Ryan L. Davis*, ,
Michael W. Mosesson# ,
Bryce A. Kerlin@ ,
Jason A. Canner@ ,
Frederick B. Ruymann@ ,
Stephen O. Brennan*,°
Fibrinogen is an essential component of the coagulation cascade and the acute phase response. The native 340 kDa molecule has a symmetrical trinodular structure composed of a central E-domain connected to outer D-domains by triple helical coiled-coils.1 Several mutations known to cause hypofibrinogenemia occur within the C-terminal gammaD-domain and have helped to elucidate the structurally and functionally important areas of this domain.2–5 Here we report the identification of a novel point mutation gammaG200V (fibrinogen Columbus) causing hypofibrinogenemia and cosegregating with three genetic thrombophilia risk factors.
The father (II.3 Figure 1) was genotypically and phenotypically normal. The mother (II.4 Figure 1) has a history of deep vein thrombosis (DVT) and heparin was administered prophylactically for her first pregnancy (III.1) and for the birth of the twins (III.3 and III.4). She displays borderline hypofibrinogenemia with a prolonged TCT (32 seconds; control 15 seconds), heterozygosity for the factor V Leiden and MTHFR C677T polymorphic mutations. The maternal grandmother (I.2; Figure 1) has a history of DVT, increased bleeding during surgery, and is heterozygous for the MTHFR C677T mutation.
The factor V Leiden mutation (and to a lesser extent MTHFR C677T) is commonly associated with thrombophilia. Thrombosis was evident with I.2 and II.4, who both experienced DVT. Subject III.4 had an intracranial sinus thrombosis and diffuse hypoxic ischemia. The FGG-H2 haplotype has recently been reported as an additional risk factor for thrombosis and involves three SNPs located in intron 8 (7874 g
a), intron 9 (9615 ct) and downstream of the polyadenylation site for exon 10 (10034 ct) of FGG. The 10034 ct htSNP is likely to result in decreased production of the alternately spliced 
prime chain, which has been reported to increase the risk of deep venous thrombosis.7 The prime chain itself is a major component of antithrombin I (fibrin) which is an important inhibitor of thrombin generation in clotting blood.8,9
Funding: RLD is the recipient of a University of Otago Postgraduate Scholarship. This project was supported by NIH grant R01 HL070627 (MWM).
Copyright © 2007 by Ferrata Storti Foundation
Disorders of Hemostasis |
Fibrinogen Columbus: a novel gamma Gly200Val mutation causing hypofibrinogenemia in a family with associated thrombophilia
* Molecular Pathology Laboratory, Christchurch School of Medicine and Health Sciences, University of Otago, Christchurch, New Zealand
° Canterbury Health Laboratories, Canterbury Hospital, Christchurch, New Zealand
# The Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI, USA
@ The Ohio State University College of Medicine Department of Pediatrics and Children’s Hospital, Columbus, OH, USA
Correspondence: Ryan Davis, Molecular Pathology Laboratory, Christchurch School of Medicine and Health Sciences, University of Otago, P.O. Box 4345, Christchurch, New Zealand. Phone: international +64.33640552. Fax: international +64.33640545. E-mail: ryan.davis{at}chmeds.ac.nz
ABSTRACT
 TOP ABSTRACT References |
|---|
Fibrinogen is an essential component of the coagulation cascade and the acute phase response. The native 340 kDa molecule has a symmetrical trinodular structure composed of a central E-domain connected to outer D-domains by triple helical coiled-coils.1 Several mutations known to cause hypofibrinogenemia occur within the C-terminal gammaD-domain and have helped to elucidate the structurally and functionally important areas of this domain.2–5 Here we report the identification of a novel point mutation gammaG200V (fibrinogen Columbus) causing hypofibrinogenemia and cosegregating with three genetic thrombophilia risk factors.
The proband is a two year old boy (III.3; Figure 1). He and his deceased twin (III.4; Figure 1) were both found to be hypofibrinogenemic with a Clauss fibrinogen of 0.3 g.L-1 at birth. Twin III.4 was noted, post-partum, to have seizure-like activity. An MRI revealed subdural and sub-arachnoid hemorrhaging as well as diffuse areas of hypoxic ischemia. Both III.3 and III.4 showed a prolonged thrombin clotting time (TCT), positive D-dimer reactivity and heterozygosity for the factor V Leiden mutation. III.4 was developmentally challenged and his neurological function continually deteriorated, resulting in death at 7 months of age due to intracranial thrombotic and hemorrhagic events. III.3 was asymptomatic postpartum and has been developmentally normal to date. The proband’s female sibling (III.1; Figure 1) is also heterozygous for the factor V Leiden mutation and has raised levels of circulating D-dimers.
 View larger version (17K): [in a new window] [Download PPT slide] |
Figure 1. Genetic pedigree showing heterozygosity for two thrombophilic mutations (factor V Leiden and MTHFR C677T) and the novel fibrinogen mutation ( Gly200Val). () Denotes individuals for whom DNA and plasma were available for fibrinogen gene analysis. Values below individuals are Clauss fibrinogen concentration (g.L–1) and FGG-H2 haplotypes for tested individuals (H2H2: homozygous; H2Hx: heterozygous; HxHx: wild type). NT: not tested.
|
DNA sequencing revealed a heterozygous GGCGTC mutation in exon 7 (c. G677T) of the fibrinogen gene (FGG). This novel 200GlyVal mutation was found in both II.4 and III.3 but was absent in II.3 Further screening for the three haplotype-tagging single nucleotide polymorphisms (htSNPs) of the FGG-H2 haplotype revealed homozygosity (H2H2) in II.3, heterozygosity (H2Hx) in III.3 and a wild type genotype (HxHx) in II.4 (Figure 1).
Normal patterns of fibrinogen chains were seen under reducing and non-reducing SDS-PAGE and chain separation by reverse-phase HPLC showed a normal pattern of peaks. Further analysis of the separated chains by electrospray ionisation mass spectrometry (ESI-MS)6 indicated a normal mass (48,374 Da) of the chain compared to a control value of 48,375 Da. This indicates no expression of the variant chain in plasma fibrinogen. The 200GlyVal mutation appears to be the direct cause of hypofibrinogenemias. It segregates with low functional and physical fibrinogen levels in the affected individuals (II.4 and III.3). This substitution has not been reported as a polymorphism and was not detected by us in 50 normal subjects. Sequence alignment of all fibrinogen chains and fibrinogen related proteins shows that the affected 200 glycine residue is totally conserved. Absolute conservation between functionally unrelated proteins and chains suggests that this residue is structurally, rather than functionally, important. Residue 200 is situated just after the first strand of the five stranded ß-sheet of the D-domain in an external bend, 3.74 Å from the side chain of tyrosine 348 (Figure 2). Mutation to valine may result in a conformational change in the area due to bulk or hydrophobicity, in turn compromising molecular integrity
 View larger version (33K): [in a new window] [Download PPT slide] |
Figure 2. Crystal structure of the D domain showing Gly200 just after the first strand of the five stranded ß sheet (1) and in close association with Tyr348. The side chain is solvent exposed, so the hydrophobic valine is likely to be poorly tolerated at this position. Furthermore, the close proximity of the bulky valine side chain to the side chain of tyrosine 348 is likely to destabilise the tertiary structure.
|
a), intron 9 (9615 ct) and downstream of the polyadenylation site for exon 10 (10034 ct) of FGG. The 10034 ct htSNP is likely to result in decreased production of the alternately spliced prime chain, which has been reported to increase the risk of deep venous thrombosis.7 The prime chain itself is a major component of antithrombin I (fibrin) which is an important inhibitor of thrombin generation in clotting blood.8,9
In conclusion, the G200V mutation found in two of the three tested individuals is the cause of hypofibrinogenemia and may contribute to the cumulative effect of other (factor V Leiden, MTHFR C677T and FGG-H2) thrombophilic mutations in this kindred.
Footnotes
Funding: RLD is the recipient of a University of Otago Postgraduate Scholarship. This project was supported by NIH grant R01 HL070627 (MWM).
References
|
TOPABSTRACTReferences |
|---|
- Mosesson MW, Siebenlist KR, Meh DA. The structure and biological features of fibrinogen and fibrin. Annals of the New York Academy of Sciences 2001;936:11-30.[Web of Science][Medline]
- Everse SJ, Spraggon G, Doolittle RF. A three-dimensional consideration of variant human fibrinogens. Thromb Haemost 1998;80:1-9.[Web of Science][Medline]
- Brennan SO, Fellowes AP, George PM. Molecular mechanisms of hypo- and afibrinogenemia. Ann NY Acad Sci 2001;936:91-100.[Web of Science][Medline]
- Matsuda M, Sugo T. Hereditary disorders of fibrinogen. Ann NY Acad Sci 2001;936:65-88.[Web of Science][Medline]
- Maghzal GJ, Brennan SO, Homer VM, George PM. The molecular mechanisms of congenital hypofibrinogenaemia. Cell Mol Life Sci 2004;61:1427-38.[Web of Science][Medline]
- Brennan SO. Electrospray ionisation analysis of human fibrinogen. Thromb Haemost 1997;78:1055-8.[Web of Science][Medline]
- Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen levels. Blood 2005;106:4176-83.
[Abstract/Free Full Text] - Mosesson MW. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003;89:9-12.[Web of Science][Medline]
- Siebenlist KR, Mosesson MW, Hernandez I, Bush LA, Di Cera E, Shainoff JR, et al. Studies on the basis for the properties of fibrin produced from fibrinogen-containing chains. Blood 2005;106:2730-6.
[Abstract/Free Full Text]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||